SEDN yields 2000000.00% · ABBV yields 3.06%● Live data
📍 SEDN pulled ahead of the other in Year 1
Combined, SEDN + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SEDN + ABBV for your $10,000?
SED International Holdings, Inc., together with its subsidiaries, distributes information technology (IT) products and solutions, computer systems, and mobility devices in the United States, Latin America, and the Caribbean. The company primarily offers complete notebook and desktop systems, peripherals and accessories, and components, as well as software and related services. It also provides fulfillment services to e-commerce customers and other resellers; IT product procurement services; and system integration and configuration services. The company sells its products through a sales force and Website to reseller customers in retail, e-commerce, value added resellers, system builders, original equipment manufacturers, and various other reseller channels. SED International Holdings, Inc. was founded in 1980 and is based in Lawrenceville, Georgia. On February 24, 2018, an involuntary petition for liquidation under Chapter 7 was filed against SED International Holdings, Inc. in the U.S. Bankruptcy Court for the Northern District of Georgia. On September 13, 2016, the involuntary petition was approved by the Court and the Chapter 7 petition was converted to Chapter 11 reorganization. The plan was later approved as Chapter 11 liquidation on June 20, 2018.
Full SEDN Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.